Business Standard

Glenmark gets DCGI nod for clinical trials of potential Covid-19 drug

As per the clinical trial protocol approved, 150 subjects with mild to moderate Covid-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care

glenmark
Premium

Glenmark Pharmaceuticals Executive Vice President, Global R&D, Sushrut Kulkarni said the company is all geared to immediately begin clinical trials on Favipiravir on Covid-19 patients in India.

BS Web TeamAgencies New Delhi
Glenmark Pharmaceuticals has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of Covid-19 patients.

Having internally developed the active pharmaceutical ingredients (API) and the formulations for the product, the company filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients on Wednesday, Glenmark Pharmaceuticals said in a statement.

The Mumbai-based company is the first pharmaceutical company in India to be given approval by the regulator to start the trial

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 30 2020 | 1:01 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com